Skip to main content

Aktis Oncology, Inc.

AKTS
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0002035832

In the last 90 days, Aktis Oncology, Inc. insiders filed 0 open-market purchases and 5 sales; 113 institutions reported holding it in 13F filings for Q2 2026, worth $1.10B in total; Soros Fund Management is the only superinvestor holding it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Aktis Oncology, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
5 filings
3 insiders, $3.23M in total
Insiders trading
3
Net value
−$3.23M
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Aktis Oncology, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Aktis Oncology, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Czibere AkosChief Medical Officer0Sep 24, 20262
Herrmann KenDirector0Jul 21, 20262
Ron-Bigger ShulamitChief Operating Officer0Jul 10, 20261
Gormley GlennDirector–Apr 16, 20261
Evnin Luke10% Owner10,260,064IndirectJan 14, 20261
MPM Oncology Innovations Fund LP10% Owner10,260,064IndirectJan 14, 20261
MPM Bioventures 2018 (B), L.P.10% Owner10,260,064IndirectJan 14, 20261
MPM Bioventures 2018, L.P.10% Owner10,260,064IndirectJan 14, 20261
MPM Asset Management Investors BV2018 LLC10% Owner10,260,064IndirectJan 14, 20261
MPM BioVentures 2018 GP LLC10% Owner10,260,064IndirectJan 14, 20261
MPM BioVentures 2018 LLC10% Owner10,260,064IndirectJan 14, 20261
MPM Oncology Innovations Fund GP LLC10% Owner10,260,064IndirectJan 14, 20261
Gadicke Ansbert10% Owner10,260,064IndirectJan 14, 20261
MPM Asset Management LLC10% Owner10,260,064IndirectJan 14, 20261
Oncology Impact Private Investment Fund 2, L.P.10% Owner10,260,064IndirectJan 14, 20261
Foley ToddDirector, 10% Owner4,235,403IndirectJan 14, 20261
Nodelman OlegDirector347,305IndirectJan 12, 20261
EcoR1 Capital, LLCDirector347,305IndirectJan 12, 20261
Vida Ventures II, LLC10% Owner157,387IndirectJan 12, 20261
Vida Ventures II-A, LLC10% Owner157,387IndirectJan 12, 20261
Kim Helen SusanDirector, 10% Owner157,387IndirectJan 12, 20261
Segal Lloyd MitchellDirector19,631IndirectJan 12, 20261

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Sep 24, 2026 (view filing)4:05 PM ETSep 231 dayCzibere AkosChief Medical OfficerSSale−12.5K$20.69−$258.6K−100.0%0 after2 lots10b5-1
Jul 21, 2026 (view filing)8:50 PM ETJul 201 dayHerrmann KenDirectorSSale−4.86K$24.56−$119.3K−100.0%0 after2 lots
Jul 20, 2026 (view filing)5:34 PM ETJul 173 daysHerrmann KenDirectorSSale−3.06K$25.21−$77.3K−100.0%0 after
Jul 10, 2026 (view filing)6:11 AM ETJul 82 daysRon-Bigger ShulamitChief Operating OfficerSSale−50.0K$27.75−$1.39M−100.0%0 after3 lots
Jul 10, 2026 (view filing)6:10 AM ETJul 82 daysCzibere AkosChief Medical OfficerSSale−50.0K$27.77−$1.39M−100.0%0 after3 lots
Jan 14, 2026 (view filing)6:19 PM ETJan 122 daysEvnin Luke and 7 others10% OwnerPPurchase+1.11M$18.00+$20.0M+12.2%10.3M afterDuplicate filing
Jan 14, 2026 (view filing)6:17 PM ETJan 122 daysGadicke Ansbert and 2 others10% OwnerPPurchase+1.11M$18.00+$20.0M+12.2%10.3M after
Jan 14, 2026 (view filing)Jan 122 daysFoley ToddDirector, 10% OwnerPPurchase+232.9K$18.00+$4.19M+5.8%4.24M after
Jan 12, 2026 (view filing)8:28 PM ETJan 12Same dayNodelman Oleg and 1 otherDirectorPPurchase+2.22M$18.00+$40.0MNew position347.3K after2 lots
Jan 12, 2026 (view filing)5:10 PM ETJan 12Same dayVida Ventures II, LLC and 1 other10% OwnerPPurchase+835.0K$18.00+$15.0MNew position157.4K after2 lotsDuplicate filing
Jan 12, 2026 (view filing)Jan 12Same dayKim Helen SusanDirector, 10% OwnerPPurchase+835.0K$18.00+$15.0MNew position157.4K after2 lots